Tag: AstraZeneca

AstraZeneca is a British–Swedish multinational pharmaceutical and biopharmaceutical company. In 2013 it moved its headquarters to Cambridge, England, and concentrated its R&D in three sites: Cambridge, Gaithersburg, Maryland (location of MedImmune) for work on biopharmaceuticals, and Mölndal (near Gothenburg) in Sweden, for research on traditional chemical drugs. In 2015 it was the eighth largest drug company in the world based on sales revenue.

Russia is one of the key markets for the company “AstraZeneca”. In October 2015 in the Kaluga region took place the grand opening of the company’s plant in Russia. Total investment in the creation of the company was $224 million. In addition, “AstraZeneca” is one of the largest companies that invest in scientific and research activities. In Russia, company conducts clinical research, which today includes more than six thousand patients. Seven and a half thousand patients participating in company studies, clinical practice. In 2016 company expanded scientific cooperation with Russian Society of Clinical Oncology and continued partnership with “Skolkovo” biomedcluster.

AstraZeneca conducts 45 clinical trials of its medicinal products in Russia

The General Director of AstraZeneca Russia & Eurasia said that the company is one of the global market leaders in terms of the relative investments in R&D

AstraZeneca will localize 10 drugs under SPIC arrangements

astrazeneca plant
In the next three years AstraZeneca intends to use the Special Investment Contract arrangements for localizing the manufacturing of 10 medicinal products

AstraZeneca signs an agreement with Tatarstan to develop R&D projects

Tatarstan Investment Development Agency and AstraZeneca signed a cooperation agreement for the development of R&D projects in the pharmaceutical industry.

AstraZeneca and leading Russian university join together their research efforts

AstraZeneca and the National Research Nuclear University MEPhI (Moscow Engineering Physics Institute) have signed a Memorandum of Intent on collaboration

AstraZeneca and Chinese fund established a drug development company

AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund to form a stand-alone company

Russia registers Tagrisso – an innovative cancer drug

AstraZeneca announced that it received the registration certificate in Russia for Tagrisso® (osimertinib)

Roivant Sciences starts cooperation with AstraZeneca

test tubes
Roivant Sciences announced that it has entered into a development partnership with AstraZeneca for a deprioritized investigational drug

Sanofi and AstraZeneca signed SPICs with the Russian Ministry

On October 16, Sanofi and AstraZeneca signed special investment contracts (SPICs) with the Russian Ministry of Industry and Trade and Russian regions

AstraZeneca obtains approval of inter-agency commission to conclude SPIC

AstraZeneca announced that it obtained the approval of inter-agency commission for the conclusion of a special-purpose investment contract

AstraZeneca starts manufacturing drug targeting cancer cells in Kaluga

astrazeneca kaluga
AstraZeneca, an international biopharmaceutical company, launched a new high-tech manufacturing process at its plant in Vorsino industrial park of Kaluga region

AstraZeneca and Takeda will develop Parkinson’s disease drug

Parkinsons disease
AstraZeneca and Takeda Pharmaceutical Company Limited today announced that they have entered an agreement to jointly develop and commercialise MEDI1341

Ethris and AstraZeneca will collaborate on mRNA therapies

Ethris GmbH, a leader in mRNA-based therapeutics, today announced a five-year strategic research collaboration with AstraZeneca and its global biologics research and development arm, MedImmune

FDA aknowledged AstraZeneca’s cancer drug as Breakthrough Therapy Designation

fda office
AstraZeneca and MedImmune yesterday announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for Imfinzi (durvalumab)

AstraZeneca and Merck started oncology collaboration

AstraZeneca and Merck & Co., Inc., known as MSD outside of the United States and Canada, today announced that they have entered a global strategic oncology collaboration

AstraZeneca invests $100 million in its hi-tech Australian facility

AstraZeneca has announced a $100 million expansion of its Sydney manufacturing facility aimed at boosting its exports to the growing Chinese market.

Chi-Med and AstraZeneca start phase III trial of kidney cancer drug

Chi-Med and AstraZeneca announced the initiation of a global pivotal Phase III, open-label, randomized multi-center registration study